Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Open-Label Study With Dendritic Cell Therapy (MesoPher) In Combination With Ex-tended-Pleurectomy/Decortication After Chemotherapy in Subjects With Resectable Mesothelioma

NCT05304208 is registered in ClinicalTrials.gov with Erasmus Medical Center as lead sponsor.

NCT NCT05304208
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05304208 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Open-Label Study With Dendritic Cell Therapy (MesoPher) In Combination With Ex-tended-Pleurectomy/Decortication After Chemotherapy in Subjects With Resectable Mesothelioma
Lead sponsor
Erasmus Medical Center
Phase
Phase 1
Overall status
Recruiting
Start date
November 2, 2021
Completion date
December 31, 2028
Enrollment
16 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mesotheliomas pleural